 WARMER, Pa., Jan. 04, 2021 GLOBE NEWSWIRE -- Arbutus Biopharma Corporation Nasdaq: ABUS, a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus HBV infection, as well as therapies to treat coronaviruses including COVID-19, today announced that the Company will participate in a virtual fireside chat at the H.C. Wainwright BioConnect 2021 Conference taking place from January 11 14, 2021. 